194 related articles for article (PubMed ID: 32346686)
1. Clinical Research of the Application of Bone Turnover Markers in Monitoring the Short-Term Therapeutic Efficacy of Vitamin D in Postmenopausal Osteoporotic women in Harbin, China.
Zhang Y; Wang Y
J Nutr Health Aging; 2020; 24(5):485-493. PubMed ID: 32346686
[TBL] [Abstract][Full Text] [Related]
2. The use of bone turnover markers for monitoring the treatment of osteoporosis in postmenopausal females undergoing total knee arthroplasty: a prospective randomized study.
Ma R; Wu M; Li Y; Wang J; Yang P; Chen Y; Wang W; Song J; Wang K
J Orthop Surg Res; 2021 Mar; 16(1):195. PubMed ID: 33731168
[TBL] [Abstract][Full Text] [Related]
3. The levels of bone turnover markers 25(OH)D and PTH and their relationship with bone mineral density in postmenopausal women in a suburban district in China.
Gao C; Qiao J; Li SS; Yu WJ; He JW; Fu WZ; Zhang ZL
Osteoporos Int; 2017 Jan; 28(1):211-218. PubMed ID: 27468899
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China.
Liao EY; Zhang ZL; Xia WB; Lin H; Cheng Q; Wang L; Hao YQ; Chen DC; Tang H; Peng YD; You L; He L; Hu ZH; Song CL; Wei F; Wang J; Zhang L
Medicine (Baltimore); 2018 Aug; 97(31):e11694. PubMed ID: 30075569
[TBL] [Abstract][Full Text] [Related]
5. The levels of bone turnover markers in Chinese postmenopausal women: Peking Vertebral Fracture study.
Zhao J; Xia W; Nie M; Zheng X; Wang Q; Wang X; Wang W; Ning Z; Huang W; Jiang Y; Li M; Wang O; Xing X; Sun Y; Luo L; He S; Yu W; Lin Q; Pei Y; Zhang F; Han Y; Tong Y; Che Y; Shen R; Hu Y; Zhou X; Xu L
Menopause; 2011 Nov; 18(11):1237-43. PubMed ID: 21747303
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
Tan W; Sun J; Zhou L; Li Y; Wu X
J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
[TBL] [Abstract][Full Text] [Related]
7. Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis.
Koldkjær Sølling AS; Harsløf T; Langdahl B
Osteoporos Int; 2019 May; 30(5):995-1002. PubMed ID: 30656367
[TBL] [Abstract][Full Text] [Related]
8. The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.
Makras P; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Anastasilakis AD
Bone; 2020 Sep; 138():115478. PubMed ID: 32534221
[TBL] [Abstract][Full Text] [Related]
9. Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study.
Sølling AS; Harsløf T; Langdahl B
J Bone Miner Res; 2021 Jul; 36(7):1245-1254. PubMed ID: 33813753
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.
Sakai A; Ito M; Tomomitsu T; Tsurukami H; Ikeda S; Fukuda F; Mizunuma H; Inoue T; Saito H; Nakamura T;
Osteoporos Int; 2015 Mar; 26(3):1193-202. PubMed ID: 25592133
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Yigu® versus Aclasta® in Chinese postmenopausal women with osteoporosis: a multicenter prospective study.
Li M; Cheng Q; Huo YN; Chao AJ; He L; Xue QY; Xu J; Yan SG; Jin H; Zhang ZL; Lin JH; Jin XL; Xu YJ; Liu F; Xia WB
Arch Osteoporos; 2022 Jan; 17(1):14. PubMed ID: 35020038
[TBL] [Abstract][Full Text] [Related]
12. Serum 25-hydroxyvitamin D and bone turnover markers in Palestinian postmenopausal osteoporosis and normal women.
Kharroubi A; Saba E; Smoom R; Bader K; Darwish H
Arch Osteoporos; 2017 Dec; 12(1):13. PubMed ID: 28124221
[TBL] [Abstract][Full Text] [Related]
13. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
14. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
[TBL] [Abstract][Full Text] [Related]
15. The impact of dietary calcium intake and vitamin D status on the effects of zoledronate.
Bourke S; Bolland MJ; Grey A; Horne AM; Wattie DJ; Wong S; Gamble GD; Reid IR
Osteoporos Int; 2013 Jan; 24(1):349-54. PubMed ID: 22893357
[TBL] [Abstract][Full Text] [Related]
16. Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate.
Olmos JM; Hernández JL; Llorca J; Nan D; Valero C; González-Macías J
J Clin Endocrinol Metab; 2012 Dec; 97(12):4491-7. PubMed ID: 23043189
[TBL] [Abstract][Full Text] [Related]
17. The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis.
Zhu HM; Qin L; Garnero P; Genant HK; Zhang G; Dai K; Yao X; Gu G; Hao Y; Li Z; Zhao Y; Li W; Yang J; Zhao X; Shi D; Fuerst T; Lu Y; Li H; Zhang X; Li C; Zhao J; Wu Q; Zhao SJ
Osteoporos Int; 2012 Apr; 23(4):1317-27. PubMed ID: 21505910
[TBL] [Abstract][Full Text] [Related]
18. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
Välimäki MJ; Farrerons-Minguella J; Halse J; Kröger H; Maroni M; Mulder H; Muñoz-Torres M; Sääf M; Snorre Øfjord E
Clin Ther; 2007 Sep; 29(9):1937-49. PubMed ID: 18035193
[TBL] [Abstract][Full Text] [Related]
19. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
Polyzos SA; Anastasilakis AD; Bratengeier C; Woloszczuk W; Papatheodorou A; Terpos E
Osteoporos Int; 2012 Mar; 23(3):1171-6. PubMed ID: 21305266
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation.
Anastasilakis AD; Polyzos SA; Yavropoulou MP; Appelman-Dijkstra NM; Ntenti C; Mandanas S; Papatheodorou A; Makras P
Calcif Tissue Int; 2021 May; 108(5):587-594. PubMed ID: 33386953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
